The European Board of Paediatrics examination assesses the basic knowledge needed to underpin paediatric training. It is as an exam for trainees who have completed at least 30-36 months of training in a recognized training program in Paediatrics, but who have not necessarily progressed to ’specialist’ training. However, it will also serve as an assessment of knowledge for trainees near the end of their training, or as an assessment of continuing knowledge for fully qualified paediatricians. It has been developed in collaboration with CESMA and the UEMS. Both have endorsed the exam.
Your Online Invigilator
During the ONLINE exam, ProctorU, an expert in remote exam invigilation, will actively monitor the exam session. The invigilator ensures smooth progress and assists with technical issues while monitoring the exam. Please note that your camera and microphone must remain active throughout the exam, and your awareness and consent for monitoring are crucial. This requirement aligns with GDPR guidelines, ensuring data protection. All exam applicants should be aware of and agree to this necessity.
To learn more, watch this video: https://meazurelearning.wistia.com/medias/x8sicg86fm.
Group rates are available to academic institutions or EAP National Societies.
If your institution/society has more than 10 candidates interested in the course, contact the EBP-EAP Exam section now.
Paediatricians training in Europe, in low or low-middle income countries, as defined by the World Bank, are entitled to a further 25% reduction. Currently this would include the Kyrgyz Republic, Moldova, Tajikistan, Ukraine and Uzbekistan.
If for any reason the exam should be postponed or cancelled, a full refund would be offered to all those who have registered by the closing date.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.